Royalties

Royalties from other partnered products not listed are either single or double digit royalties as described under collaborative research and development programs in the current 10-K. Not all royalties are disclosed due to confidentiality requirements.

 

 

Eltrombopag (PROMACTA™)(1)(2)                      
4.7%
6.6%
7.5%
9.4%
9.3%		Less than $100M annual sales
On portion of sales in range of $100M - $200M
On portion of sales in range of $200M - $400M
On portion of sales greater than $400M
On portion of sales greater than $1.5B
LGD-4665(2) 14.5%All sales (6.5% for first year sales)
AVINZA®(1) 5%If sales are less than $200M annually
Higher royalties paid if sales exceed $200M
Bazedoxifene (VIVIANT™)
Basedoxifene (APRELA™)


 0.5%
1.5%
2.5%

3%		Less than $400M annual sales
On portion of sales in range of $400M - $1.0B annually
On portion of sales greater than $1B annually

All sales
Tanzisertib 2%All sales

(1)

 Currently receiving royalty payments

(2)

 Net of payments due to The Rockefeller University.

(3)

 If GSK exercises its Proof of Concept (PoC) Option for a particular Target, Ligand may continue the development until PoC and receive stepped up royalties ranging from 10% to 14% under the categories of annual sales described above.

Back to Top